Table 1 Prior randomized controlled trial data for painful diabetic neuropathy
Treatment | Number | Average baseline pain | Average pain post-treatment | Responder rate | Length of follow-up | Reference |
|---|---|---|---|---|---|---|
Pregabalin | 76 | 6.5 | 4.0 | 40% | 8 wks | [14] |
82 | 6.2 | 3.6 | 48% | 5 wks | [15] | |
82 | 6.7 | 4.3 | 39% | 6 wks | [16] | |
82 | 6.3 | 3.5 | 49% | 13 wks | [17] | |
101 | 6.7 | 3.7 | 46% | 12 wks | [18] | |
134 | 6.9 | 4.3 | 38% | 12 wks | [19] | |
66 | 6.5 | 4.8 | 21% | 13 wks | [20] | |
96 | NR | NR | 47% | 16 wks | [21] | |
123 | 7.1 | 2.0 | NR | 12 wks | [22] | |
Duloxetine | 113 | 5.9 | 2.7 | 52% | 12 wks | [23] |
116 | 5.5 | 3.0 | 50% | 12 wks | [24] | |
112 | 6.2 | 3.4 | 53% | 12 wks | [25] | |
106 | 5.5 | 2.8 | 57% | 12 wks | [26] | |
32 | NR | NR | 59% | 8 wks | [27] | |
138 | 7.1 | 4.0 | 42% | 12 wks | [19] | |
57 | 6.6 | 3.8 | NR | 8 wks | [28] | |
67 | NR | NR | 28% | 16 wks | [21] | |
Tapentadol | 199 | NR | NR | 38% | 15 wks | [29] |
12 | 6.5 | 3.9 | NR | 4 wks | [30] | |
168 | 7.3 | 4.4 | 40% | 15 wks | [31] | |
Low-frequency SCS | 40 | 7.3 | 3.1 | 60% | 6 mos | [32] |
22 | 7.3 | 4.0 | 47% | 24 mos | [33] |